Stockscreener 앱 받기
1.23
1.40%
-0.0175
전일 마감가:
$1.2475
열려 있는:
$1.2
하루 거래량:
21,899
Relative Volume:
0.03
시가총액:
$8.52M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-8.89%
1개월 성능:
+23.00%
6개월 성능:
+108.47%
1년 성능:
+0.00%
1일 변동 폭
$1.16
$1.2667
1주일 범위
$1.16
$1.3699
52주 변동 폭
$0.45
$3.80
Chromocell Therapeutics Corp Stock (CHRO) Company Profile
명칭
Chromocell Therapeutics Corp
전화
(917) 644-6313
주소
685 US HIGHWAY ONE, NORTH BRUNSWICK
CHRO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CHRO
Chromocell Therapeutics Corp
|
1.2001 | 8.52M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.07 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
513.72 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.13 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
539.36 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.07 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Chromocell Therapeutics Corp 주식(CHRO)의 최신 뉴스
Channel Therapeutics Faces Financial Uncertainty as Auditors Issue Going Concern Warning - Stock Titan
Ligand Pharmaceuticals to Merge Units With Channel Therapeutics to Launch Pelthos Therapeutics - marketscreener.com
Gold Falls Over 1%; D.R. Horton Posts Downbeat Earnings - Benzinga
Ligand subsidiaries, Chromocell Therapeutics to merge - TipRanks
Ligand Subsidiary Pelthos Therapeutics To Combine With Channel Therapeutics - marketscreener.com
Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics - GlobeNewswire Inc.
Channel Therapeutics Corporation announced that it has received $0.25 million in funding -February 24, 2025 - Marketscreener.com
Channel Therapeutics secures $325,000 promissory note By Investing.com - Investing.com Australia
Channel Therapeutics secures $325,000 promissory note - Investing.com India
New Biotech Stocks at Investorideas.com - Investorideas.com newswire
Wall Street-Heavily Traded - WDRB
Biopharma IPOs rebound slightly, as class of 2024 lags with a 29% average decline - BioWorld Online
Channel Therapeutics Advances Novel Pain Treatment Strategy with NaV1.7 Inhibitor Pipeline - StockTitan
Channel Therapeutics' Pain Treatment Breakthrough: Novel Nerve Block Outperforms Standard Care in Key Trial - StockTitan
Chromocell changes name to Channel Therapeutics, provides program updates - Nasdaq
Channel Therapeutics finalizes corporate restructuring - Investing.com
Chromocell Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain - The Manila Times
Chromocell to Present at Upcoming Fall Investor Conferences - StockTitan
Chromocell Therapeutics amends stock repurchase plan - TradingPedia
Chromocell Announces Amendment to Stock Repurchase Plan | CHRO Stock News - StockTitan
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing - GlobeNewswire
Another Delaware Publicly Traded Company Proposes A Nevada Move | Allen Matkins - JD Supra
Chromocell to Participate in Life Sciences Investor Forum September 19th - Yahoo Finance
CDMO Benuvia Appoints Terry Novak As New CEO - Pharmaceutical Online
IPO class of 2024 shows value recovery despite mixed stock performance - BioWorld Online
Healthy Returns: Biotech IPOs ramped up to start 2024, but the market hasn't fully recovered just yet - CNBC
Why Super Micro Computer Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Friday's Mid-Day Session - TradingView
Chromocell Issues Letter to Stockholders from Chief Executive Officer - StockTitan
Chutes & Ladders—Bayer undergoes leadership shake-up - Fierce Biotech
Are there bright times for biotech IPOs ahead? - European Biotechnology Magazine
Sidoti Events, LLC's Virtual March Small-Cap Conference - Yahoo Finance
Chromocell Therapeutics Announces Closing of Initial Public Offering for Gross Proceeds of $6.6 Million - Stock Titan
CHRO Stock Price and Chart — AMEX:CHRO - TradingView
CHROChannel Therapeutics Corporation Latest Stock News & Market Updates - StockTitan
CHRO IPO NewsPain relief biotech Chromocell Therapeutics sets terms for $9 million IPO - renaissancecapital.com
Biotech Venture in the UAE Validated by IPO in the U.S. - PR Newswire
Tina Garyantes – Feliciano Center For Entrepreneurship And Innovation - Montclair State University
Stocks Telegraph - Stocks Telegraph
Nestlé and Chromocell Extend Collaboration to Find Alternatives to Salt - Food Manufacturing
Improving the Reliability and Utility of Streptozotocin‐Induced Rat Diabetic Model - Wiley Online Library
Chromocell Announces Initiation of Multiple Ascending Doses Portion of Phase 1 Clinical Trial - PR Newswire
Chromocell and Astellas Announce FDA Fast Track Designation and First Subject Dosing with Lead Candidate CC8464/ASP1807 for the Management of Neuropathic Pain Associated with iSFN - PR Newswire
News from Central Jersey's pharma, biotech industries - Central New Jersey News
Astellas, Chromocell Launch Up-to-$515M+ Pain Drugs Collaboration - Genetic Engineering and Biotechnology News
Chromocell Therapeutics Corp (CHRO) 재무 분석
Chromocell Therapeutics Corp (CHRO)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Chromocell Therapeutics Corp 주식 (CHRO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Francis Knuettel II | CEO, Pres., CFO, Treas & Secty |
Sep 13 '24 |
Buy |
0.97 |
3,500 |
3,395 |
547,710 |
| Francis Knuettel II | CEO, Pres., CFO, Treas & Secty |
Sep 12 '24 |
Buy |
0.97 |
1,700 |
1,649 |
544,210 |
| Francis Knuettel II | CEO, Pres., CFO, Treas & Secty |
Sep 10 '24 |
Buy |
0.89 |
6,500 |
5,785 |
537,010 |
| Francis Knuettel II | CEO, Pres., CFO, Treas & Secty |
Sep 11 '24 |
Buy |
0.94 |
5,500 |
5,170 |
542,510 |
1.59%
0.56%
자본화:
|
볼륨(24시간):